Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials

Table 3 AEs and SAEs in patients who received SZC 10 g in the pooled correction phase

Parameter, n (%)	Overall (N = 170)	Baseline Serum K⁺ level (mmol/L)
Parameter, n (%)	Overall (N = 170)	5.5–< 6.0 (n = 125)	6.0–6.5 (n = 39)	> 6.5 (n = 6)
Any AEs^a	15 (8.8)	7 (5.6)	8 (20.5)	0 (0.0)
Gastrointestinal disorders	5 (2.9)	2 (1.6)	3 (7.7)	0 (0.0)
Constipation	3 (1.8)	1 (0.8)	2 (5.1)	0 (0.0)
Diarrhea	1 (0.6)	0 (0.0)	1 (2.6)	0 (0.0)
Peripheral edema	1 (0.6)	0 (0.0)	1 (2.6)	0 (0.0)
Upper respiratory tract infection	1 (0.6)	0 (0.0)	1 (2.6)	0 (0.0)
Blood glucose decreased	1 (0.6)	0 (0.0)	1 (2.6)	0 (0.0)
Headache	1 (0.6)	0 (0.0)	1 (2.6)	0 (0.0)
Cough	1 (0.6)	0 (0.0)	1 (2.6)	0 (0.0)
Ecchymosis	1 (0.6)	0 (0.0)	1 (2.6)	0 (0.0)
Serious AEs	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)

AE adverse event, K⁺ potassium, SAE serious adverse event, SZC sodium zirconium cyclosilicate
^aAny AE that occurred in > 2% of patients, regardless of relation to study drug. Bold text indicates total number of events

ISSN: 1471-2369